KNW Know Labs Corporation: ערך חשבונאי למניה

Know Labs, Inc. (KNW) is developing non-invasive diabetes monitoring as it pursues FDA certification. The primary obstacles remain the high cost of device production and stringent data accuracy requirements, although biosensor manufacturing capacities are operating stably. An analysis of the book value per share confirms the capital dynamics, where -0.80 serves as the current metric, reflecting the value of net assets.

The capital stability of Know Labs, Inc. (KNW) during periods of volatility is confirmed through an analysis of net assets minus liabilities. While management secures capitalization through the patenting of non-invasive sensors and clinical trials, the book value per share trend demonstrates the fundamental reliability of the business. The growth of this metric indicates an increase in equity, creating a defensive barrier for the investor's portfolio.